Medtech M&A outlook in 2024
January 31, 2024
Medtech M&A outlook in 2024January 31, 2024 One of the challenges facing dealmakers across all sectors is being able to navigate the rapidly evolving dynamics of the current market. Will the pieces fall in to place in 2024?Transacting in present times is arguably more complicated than ever, with macro-economic and geopolitical uncertainty fuelling disparity between buyers and sellers on valuation, an increasingly interventionist regulatory environment and other well-publicised external factors contributing to longer and more fragile deal processes. Counteracting these pressures to an extent within the health and life sciences sector is the ever-present need for investment in products, processes, R&D and infrastructure. With healthcare systems facing increasing capacity challenges and life sciences businesses actively seeking new drugs, technologies and devices, this investment imperative sits alongside a systemic drive towards new technologies and AI-enabled platforms. As a result, Medtech and other digital health solutions remain strategically crucial tools for the industry. Following a softer end to M&A in 2023 than some might have anticipated, will 2024 be the year that activity in the Medtech space accelerates? A genuine feeling of optimismThe general market sentiment is that an uplift in M&A activity within the sector is expected in 2024, with a number of stakeholders going as far as to forecast very significant increases in deal volumes. In particular, as widely stated in industry analysis and surveys, corporates are expected (and are expecting) to be major contributors to dealmaking encouraged by various factors including a more stable and predictable interest rate environment , high levels of readily available cash on balance sheets and easing of other commercial constraints. When one factors in the growing trend for non-traditional corporates (i.e. large tech companies) entering the healthcare sector via acquisition, the scene would certainly appear to be set for a stronger 2024 when it comes to corporate-driven Medtech M&A. Alongside corporate optimism, sustained or increased activity at the start-up and new entrant level is anticipated, albeit not necessarily manifesting through significant increases in new VC investments but in a movement towards consolidation between complementary solutions and bolt-on acquisitions. The buzz around Generative AI that has been witnessed over the last 24 months, for example, has resulted in a relative proliferation of AI-based point solutions and we anticipate that as these businesses come to seek further investment or growth they may turn to M&A solutions in order to realise synergies and increase valuations, especially if other sources of funding remain not as readily forthcoming. In addition, potential trade buyers are increasingly looking for more sophisticated and integrated platforms rather than isolated solutions, which in turn drives combinations of technologies. Private equity funds remain an important part of the M&A ecosystem in the sector, albeit having had a quieter 2023. Activity is expected to increase in 2024 as pressures to return value to investors grow alongside ever-increasing levels of dry powder but quite how active private equity will be in 2024 remains to be seen. GenAI and Remote Patient Monitoring (“RPM”)Broader industry and governmental investment in things such as RPM assets, medical devices and AI-powered diagnostics show no sign of slowing down and economic growth is expected across all these areas. When taken alongside the transactional dynamics set out above, we anticipate that AI and RPM technologies will prove to be two prevalent contributors to sector M&A activity in 2024. It is well publicised that GenAI has the genuine potential to transform and revolutionise the industry, not only within clinical and drug discovery (in terms of saving time and increasing efficiency and accuracy) but also in more day-to-day systems and operations. We have recently acted on transactions involving AI-based laboratory information management systems for example, and on deals involving AI platforms designed to more effectively manage patient pathways. Now that the direction of travel in the AI regulatory landscape is becoming slowly clearer, with the risk-based approach proposed in Europe and early signs of the approach the US may take, businesses have a sense of confidence about the sustained viability and commercial application of GenAI and governmental support of the same, which can be expected to further increase confidence in such solutions. As for RPM technologies, there is sustained growing demand for products both from consumers but also perhaps more significantly from health insurance companies and other healthcare providers. Such devices have the ability to enhance early detection of serious conditions and thereby improve patient outcomes, which sits neatly within the principles of a value-based care approach, and also contribute to the development of more personalised medicines. Furthermore, the increased availability of data resulting from the mass use of such devices further fuels the effectiveness of clinical research and indeed GenAI platforms. We therefore expect businesses focussed on the development, distribution and selling of RPM solutions to be especially attractive targets in 2024 for corporates and investors alike. We are excited to see what 2024 has in store for businesses, and transactions, in these areas and our Global teams are on standby to support. Further reading on GenAINavigating the Murky Waters of AI, Deepfakes, and Image Rights: Protecting Your Digital Identity* Education webinar- Generative AI in education - April 30 2024 Education webinar- Generative AI in education - September 18 2024 Latest InsightsLatest News
Latest Events
legal updates November 18, 2026 UK: FCA releases new ESG ratings rules legal updates November 18, 2026 UK: AI Transcription – harness benefits, manage risks legal updates November 18, 2026 Commercially Connected shorts - 18 November 2026 legal updates November 18, 2026 COP31: Oceans, nature and land use gain ground in climate policy and inves... deal alerts November 06, 2026 Eversheds Sutherland advises Mercedes-Benz on European fast-charging partne... firm news November 05, 2026 Eversheds Sutherland hires partner Peter Cheng to lead Hong Kong ECM practi... firm news October 27, 2026 Eversheds Sutherland (International) announces senior leadership appointmen... firm news October 26, 2026 Eversheds Sutherland deepens fintech and regulatory bench with double partn... hybrid Europe Action Week 2026 Europe Action Week returns this November with a dynamic mix of events designed to help you navigate what’s next. in-person Industrial relations masterclass November 18, 2026 9.30am - 4.30pm (GMT) London, United Kingdom virtual Education Webinar - Equality, diversity and inclusion: current developments... November 18, 2026 11:00AM - 12:00PM virtual Education Webinar - Protecting your IP when contracting with third parties ... November 19, 2026 11:00AM - 12:00PM |